Hexavalent Vaxelis

Vaccine in vial with syringe. Vaccination concept. 3d
ACIP group unanimously voted to add the new hexavalent vaccine, Vaxelis –which protects against diphtheria, tetanus, pertussis, polio, hepatitis B and Haemophilus influenzae type B and was licensed by the Food and Drug Administration (FDA) Fall 2018 – to the Vaccines for Children (VFC) program. This vote allows the hexavalent vaccine to be included in the infant series at ages 2, 4 and 6 months through the VFC program, which provides immunizations to children whose families who do not have health insurance or who cannot afford vaccination.
The addition of another combo vaccine allows for less injection and discomfort for many children as to get this before now would be 2 rather than 1 injection.
• VAXELIS is approved for use as a 3 dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).